BG102880A - Cation virosomes as transfer systems for genetic materials - Google Patents

Cation virosomes as transfer systems for genetic materials

Info

Publication number
BG102880A
BG102880A BG102880A BG10288098A BG102880A BG 102880 A BG102880 A BG 102880A BG 102880 A BG102880 A BG 102880A BG 10288098 A BG10288098 A BG 10288098A BG 102880 A BG102880 A BG 102880A
Authority
BG
Bulgaria
Prior art keywords
virosomes
cation
preparation
transfer systems
genetic materials
Prior art date
Application number
BG102880A
Other languages
Bulgarian (bg)
English (en)
Inventor
Ernst WAELTI
Reinhard Glueck
Peter Klein
Original Assignee
Nika Health Products Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Limited filed Critical Nika Health Products Limited
Publication of BG102880A publication Critical patent/BG102880A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BG102880A 1996-05-08 1998-10-29 Cation virosomes as transfer systems for genetic materials BG102880A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96107282 1996-05-08
PCT/EP1997/002268 WO1997041834A1 (en) 1996-05-08 1997-05-04 Cationic virosomes as transfer system for genetic material

Publications (1)

Publication Number Publication Date
BG102880A true BG102880A (en) 1999-05-31

Family

ID=8222763

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102880A BG102880A (en) 1996-05-08 1998-10-29 Cation virosomes as transfer systems for genetic materials

Country Status (28)

Country Link
US (1) US6210708B1 (enExample)
EP (1) EP0902682A2 (enExample)
JP (1) JP2000509404A (enExample)
KR (1) KR100536983B1 (enExample)
CN (1) CN1271992C (enExample)
AR (1) AR007054A1 (enExample)
AU (1) AU710170B2 (enExample)
BG (1) BG102880A (enExample)
BR (1) BR9709224A (enExample)
CA (1) CA2253561A1 (enExample)
CO (1) CO4600638A1 (enExample)
CZ (1) CZ299809B6 (enExample)
EA (1) EA003130B1 (enExample)
GT (1) GT199700058A (enExample)
HR (1) HRP970234B1 (enExample)
HU (1) HUP9901790A3 (enExample)
ID (1) ID17934A (enExample)
NO (1) NO327726B1 (enExample)
NZ (1) NZ332666A (enExample)
OA (1) OA10916A (enExample)
PA (1) PA8429201A1 (enExample)
PE (1) PE65198A1 (enExample)
PL (1) PL199201B1 (enExample)
SK (1) SK152698A3 (enExample)
SV (1) SV1997000032A (enExample)
TN (1) TNSN97080A1 (enExample)
WO (1) WO1997041834A1 (enExample)
ZA (1) ZA973885B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
EP1011735A1 (en) * 1997-09-08 2000-06-28 Promega Corporation METHOD OF $i(IN VIVO) TRANSFORMATION UTILIZING LIPID VEHICLES
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
ES2215073T3 (es) * 1999-10-08 2004-10-01 Nika Health Products Limited Virosomas de dosper cationicos.
JP4112860B2 (ja) * 1999-12-17 2008-07-02 ショット アクチエンゲゼルシャフト 乗員の拘束システムの誘導作動式点火カプセルおよび点火カプセル用のテスト回路
WO2001052901A1 (en) * 2000-01-21 2001-07-26 Hisamitsu Pharmaceutical Co., Inc. Drugs for gene therapy
EP1409653A4 (en) * 2001-07-23 2006-05-03 Onyx Pharma Inc IN HUMAN TARGET CANCELLS SELECTIVELY REPLICATING VIRUS MUTANTS
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
CN100488491C (zh) * 2002-11-21 2009-05-20 派维翁生物技术有限公司 高效融合小泡,其制备方法和含有该小泡的药物组合物
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
CA2663034C (en) 2006-09-15 2016-05-03 Ottawa Health Research Institute Oncolytic rhabdovirus
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
WO2013050048A2 (en) * 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses
WO2018060213A1 (en) 2016-09-27 2018-04-05 Camurus Ab Formulations containing a somatostatin receptor agonist
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
JPH06500128A (ja) * 1991-05-08 1994-01-06 シュバイツ・ゼルム―・ウント・インプフィンスティテュート・ベルン 免疫刺激及び免疫増強性再構成インフルエンザウイロソーム及びそれを含有するワクチン
AU3614493A (en) 1992-02-04 1993-09-01 Chiron Corporation Non-toxic lipid vaccine formulations
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
JPH10505320A (ja) * 1994-05-31 1998-05-26 イネックス ファーマシューティカルズ コーポレイション 治療剤のビロゾーム媒介細胞内輸送
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale

Also Published As

Publication number Publication date
CN1271992C (zh) 2006-08-30
NO985137L (no) 1999-01-04
HUP9901790A2 (hu) 1999-08-30
SV1997000032A (es) 1998-03-27
BR9709224A (pt) 1999-08-10
PL329853A1 (en) 1999-04-12
OA10916A (en) 2003-02-21
KR100536983B1 (ko) 2006-06-29
JP2000509404A (ja) 2000-07-25
TNSN97080A1 (fr) 2005-03-15
NO327726B1 (no) 2009-09-14
ID17934A (id) 1998-02-12
PE65198A1 (es) 1998-10-16
AR007054A1 (es) 1999-10-13
HRP970234A2 (en) 1998-06-30
EA199800992A1 (ru) 1999-06-24
ZA973885B (en) 1998-11-06
HRP970234B1 (en) 2002-04-30
NZ332666A (en) 2000-05-26
CA2253561A1 (en) 1997-11-13
US6210708B1 (en) 2001-04-03
CZ361498A3 (cs) 1999-03-17
EP0902682A2 (en) 1999-03-24
EA003130B1 (ru) 2003-02-27
KR20000010780A (ko) 2000-02-25
GT199700058A (es) 1998-10-29
CN1225007A (zh) 1999-08-04
HUP9901790A3 (en) 2010-11-29
SK152698A3 (en) 1999-05-07
WO1997041834A1 (en) 1997-11-13
AU2776697A (en) 1997-11-26
PA8429201A1 (es) 2000-05-24
CZ299809B6 (cs) 2008-12-03
CO4600638A1 (es) 1998-05-08
PL199201B1 (pl) 2008-08-29
NO985137D0 (no) 1998-11-04
AU710170B2 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
BG102880A (en) Cation virosomes as transfer systems for genetic materials
Seyedin et al. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone.
Butler The nature and significance of osteopontin
Kasugai et al. Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter
Ihle et al. Phenotypic characteristics of cell lines requiring interleukin 3 for growth.
Brunner et al. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells
Wang et al. Purification and characterization of other distinct bone-inducing factors.
Nilsen-Hamilton et al. Selective stimulation by mitogens of incorporation of 35S-methionine into a family of proteins released into the medium by 3T3 cells
CA2457632C (en) Identification and isolation of somatic stem cells and uses thereof
Guy et al. Coordinated action of IgE and a B-cell-stimulatory factor on the CD23 receptor molecule up-regulates B-lymphocyte growth.
Stadie et al. Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP‐GalNAc: polypeptide N‐acetylgalactosaminyltransferase from milk or mammary carcinoma cells
ZA953629B (en) Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies
AU2002355970A1 (en) Identification and isolation of somatic stem cells and uses thereof
AU3509995A (en) Overexpression of mammalian and viral proteins
KR20010030617A (ko) 유방 특이적으로 분비되는 유방암 단백질인 마마글로빈
Atherton et al. Dipeptidyl peptidase IV expression identifies a functional sub‐population of breast fibroblasts
Schwartz-Albiez et al. Differential expression of annexins I and II in normal and malignant human mammary epithelial cells
WO2000043499A3 (en) ANTI-TRANSFORMING GROWTH FACTOR BETA (TGF-β) TREATED STEM CELL COMPOSITION AND METHOD
GB9722320D0 (en) Human cell cycle checkpoint proteins
Clark et al. Characterization of murine pregnancy decidua transforming growth factor b. I. Transforming growth factor b2-like molecules of unusual molecular size released in bioactive form
López-Moratalla et al. Activation of human lymphomononuclear cells by peptides derived from extracellular matrix proteins
Davidson et al. Characterization of a signal peptide sequence in the cell-free translation product of sheep elastin mRNA
Bocchini et al. Glial fibrillary acidic protein and its encoding mRNA exhibit mosaic expression in a glioblastoma multiform cell line of clonal origin
Avnur et al. Spatial interrelationships between proteoglycans and extracellular matrix proteins in cell cultures
Mizuno et al. The osteoblastic MC3T3-E1 cells synthesized C-terminal propeptide of type I collagen, which promoted cell-attachment of osteoblasts